Biofeedback is a well-known and effective treatment for patients with fecal evacuation disorder (FED). The main purpose of this study was to investigate the outcome and the effects of biofeedback therapy on physiological parameters as assessed by manometry in patients with FED. Data from 114 consecutive patients with FED who underwent biofeedback therapy in Sara Gastrointestinal clinic in Tehran, Iran during 2015–2018 were retrospectively reviewed and analyzed. All participants underwent a comprehensive evaluation of anorectal function that included anorectal manometry and a balloon expulsion test at the baseline and after biofeedback therapy. Maximum anal squeeze pressure and sustained anal squeeze pressure were improved up to 100% and 94.7% of normal values in the patients after biofeedback, respectively (P < 0.001). First rectal sensation, was significantly decreased (25 ± 18.5 vs. 15.5 ± 5.2) while the maximum tolerable volume was significantly increased (233.6 ± 89.7 vs. 182.4 ± 23.1) after biofeedback therapy (P < 0.001). Type I dyssynergia was the most common type, effecting 82 cases (71.9%) of our patients. Dyssynergia parameters were improved 50–80% in 34 (41.5%) and 10 (31.3%) type I and non-type I patients, respectively. Over 80% improvement of dyssynergia parameters occurred in 48 (58.5%) and 22 (68.8%) type I and non-type I patients, respectively. These differences were not statistically significant between the two groups (P = 0.3). In addition, the ability to reject the balloon was significantly better in post intervention measurements (P < 0.001). Biofeedback not only improves the symptoms in patients of FED but also reverses more than 80% the dyssynergic parameters of defecation. However, due to the general effectiveness of biofeedback treatment in different types of DD, there were no significant differences between their improvement scores.

生物反馈是一种众所周知且有效的治疗排便障碍 (FED) 患者的方法。本研究的主要目的是调查生物反馈疗法对 FED 患者通过测压评估的生理参数的结果和影响。对 2015-2018 年在伊朗德黑兰 Sara 胃肠诊所接受生物反馈治疗的 114 名连续 FED 患者的数据进行了回顾性分析和分析。所有参与者都接受了肛门直肠功能的综合评估，包括在基线和生物反馈治疗后进行肛门直肠测压和球囊排出试验。生物反馈后患者的最大肛门挤压压力和持续肛门挤压压力分别提高到正常值的100%和94.7%（P < 0.001）。第一次直肠感觉，生物反馈治疗后显着降低（25±18.5 vs. 15.5±5.2），而最大耐受量显着增加（233.6±89.7 vs. 182.4±23.1）（P < 0.001）。I 型协同失调是最常见的类型，影响了我们的 82 例 (71.9%) 患者。34 名 (41.5%) 和 10 名 (31.3%) I 型和非 I 型患者的协同失调参数分别改善了 50-80%。超过 80% 的协同失调参数改善分别发生在 48 (58.5%) 和 22 (68.8%) 名 I 型和非 I 型患者中。这些差异在两组之间没有统计学意义（P = 0.3）。此外，在干预后测量中，拒绝球囊的能力明显更好（P < 0.001）。生物反馈不仅可以改善 FED 患者的症状，而且可以逆转 80% 以上的排便失调参数。然而，由于生物反馈治疗对不同类型 DD 的一般有效性，它们的改善分数之间没有显着差异。